Pharmaceuticals

Global Viral Vector Production (Research-Use) Market Projected to Expand at 15% CAGR by 2029

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Viral Vector Production (Research-Use) Market Expected To Become By 2029 Compared With Its 2025 Level?

The market size for viral vector production (research-use) has seen swift expansion in recent years. It is expected to rise from $1.54 billion in 2024 to $1.77 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 15.4%. The expansion observed in the past can be attributed to the development of basic genetic and cell biology research, an increase in infectious disease research, the widespread application of viral vectors in CRISPR and RNAi studies, the growing demand from cancer immunotherapy studies, and increasing academic interest alongside initial clinical trials in gene therapy.

The market for viral vector production (research-use) is anticipated to experience swift expansion in the coming years. Its valuation is projected to reach $3.10 billion by 2029, growing at a compound annual growth rate (CAGR) of 15.0%. This expansion during the projection period can be attributed to factors such as the increasing prevalence of genetic disorders, the expanding preclinical gene therapy pipeline, wider application in regenerative medicine investigations, intensified research into neurodegenerative diseases, and augmented funding for rare disease research. Key trends anticipated during this period encompass progress in gene therapy research, the implementation of automation in vector quality control (QC), the development of hybrid and chimeric vectors, automated upstream and downstream processes, and vector modification utilizing synthetic biology.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28350&type=smp

What Are The Key Drivers Of Growth In The Viral Vector Production (Research-Use) Market?

The increasing incidence of genetic conditions is anticipated to drive the expansion of the viral vector production (research-use) market in the foreseeable future. These disorders are defined as illnesses or states arising from irregularities in a person’s deoxyribonucleic acid, potentially passed down from one or both parents, or resulting from spontaneous genetic mutations. The surge in genetic disorders is linked to the growing age of parents, which heightens the probability of genetic mutations being transmitted to their children. The expanding commonness of genetic disorders supports the growth of viral vector production (research-use) by stimulating the need for sophisticated gene delivery instruments for investigating disease mechanisms and formulating prospective therapeutic strategies. As an illustration, in November 2024, data from the Centers for Disease Control and Prevention (CDC), a U.S. government public health organization, indicated that Trisomy 21 (Down syndrome) affects approximately 1 in 643 births, leading to around 5,713 new instances each year, while Trisomy 18 is observed in roughly 1 in 3,336 births, equating to about 1,101 cases annually. Consequently, the escalating frequency of genetic disorders is expected to fuel the expansion of the viral vector production (research-use) market.

Which Key Segments Fueling The Viral Vector Production (Research-Use) Market?

The viral vector production (research-use) market covered in this report is segmented as

1) By Type: Adeno-Associated Virus (AAV), Lentivirus, Adenovirus, Retrovirus, Other Types

2) By Production: Transient Transfection, Stable Cell Line, Viral Packaging System, Other Production Methods

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene Therapy, Vaccines, Oncology, Infectious Diseases, Other Applications

5) By End-Use: Pharmaceutical And Biopharmaceutical Companies, Research Institutes

Subsegments:

1) By Adeno-Associated Virus: Single-Stranded Adeno-Associated Virus, Self-Complementary Adeno-Associated Virus, Hybrid Adeno-Associated Virus

2) By Lentivirus: Human Immunodeficiency Virus-Based Lentivirus, Feline Immunodeficiency Virus-Based Lentivirus, Equine Infectious Anemia Virus-Based Lentivirus

3) By Adenovirus: Replication-Competent Adenovirus, Replication-Deficient Adenovirus, Helper-Dependent Adenovirus

4) By Retrovirus: Gamma Retrovirus, Spumavirus (Foamy Virus), Alpha Retrovirus

5) By Other Types: Herpes Simplex Virus Vectors, Baculovirus Vectors, Sendai Virus Vectors

Which Key Trends Are Expected To Influence The Viral Vector Production (Research-Use) Market In The Coming Years?

Leading firms in the viral vector production market are concentrating on creating cutting-edge solutions, like tailored cell culture media, to enhance transfection efficiency, elevate viral vector output, and guarantee reliable quality for research purposes. These media are nutrient-dense liquids formulated to sustain cell growth and upkeep when cells are cultured outside their native conditions. They incorporate vital elements such as amino acids, vitamins, and growth factors, precisely optimized for particular cell types and their uses. As an example, in January 2023, FUJIFILM Irvine Scientific, a US-based life sciences company, launched BalanCD HEK293 Viral Feed, which is recognized as the world’s inaugural chemically defined nutrient feed, specifically tailored for HEK293 suspension cultures employed in AAV viral vector manufacturing. With this introduction, the company intends to substantially increase adeno-associated virus (AAV) yields, demonstrating an improvement of up to 67% in viral packaging efficiency when contrasted with basal media. This feed is engineered for scalable gene therapy and biotechnology processes, providing reliable performance across various formats and ensuring compatibility with diverse media systems.

Which Global Market Leaders Are Shaping The Future Of The Viral Vector Production (Research-Use) Sector?

Major companies operating in the viral vector production (research-use) market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza Group AG, Sartorius AG, Charles River Laboratories International Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Curia Inc., AGC Biologics GmbH, SK pharmteco Inc., Oxford Biomedica Plc, Waisman Biomanufacturing, Voyager Therapeutics Inc., FinVector Oy, Batavia Biosciences BV., GENEZEN LABORATORIES, BioNTech IMFS GmbH, VGXI Inc., Tonix Pharmaceuticals, Cell and Gene Therapy Catapult, and Mustang Bio Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/viral-vector-production-research-use-global-market-report

What Regional Growth Trends Are Shaping The Viral Vector Production (Research-Use) Market Outlook?

North America was the largest region in the virtual vector production (research-use) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in viral vector production (research-use) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Viral Vector Production (Research-Use) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28350&type=smp

Browse Through More Reports Similar to the Global Viral Vector Production (Research-Use) Market 2025, By The Business Research Company

Viral Vector Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Viral And Non Viral Vector Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Oral Expectorant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795